ETF Holdings Breakdown of BMRN

Stock Name	Biomarin Pharmaceutical Inc
Ticker	BMRN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US09061G1013
LEI	NSLL8ITTRR0J5HEMR848

BMRN institutional holdings

The following institutional investment holdings of BMRN have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2026-02-09	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	2,642	USD 152,734 -0.6%	57.81
2026-02-09	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	3,945	USD 228,060	57.81
2026-02-09	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	14,864	USD 859,288 -0.6%	57.81
2026-02-09	IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc)	782	USD 45,207	57.81
2026-02-09	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,333	USD 77,061	57.81
2026-02-09	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	21,835	USD 1,262,281	57.81
2026-02-09	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	140,306	USD 8,111,090	57.81
2026-02-09	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	141,475 0.9%	USD 8,178,670 0.7%	57.81
2026-02-09	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	140,306	USD 8,111,090	57.81
Total =	467,488	USD 27,025,481

News associated with BMRN

BioMarin Pharmaceutical (NASDAQ:BMRN) Coverage Initiated at HC Wainwright: HC Wainwright assumed coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) in a note issued to investors on Monday, MarketBeat.com reports. The firm set a “neutral” rating and a $60.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 7.74% from the stock’s previous […] - 2025-09-10 03:13:10
9,709 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Bought by Atria Wealth Solutions Inc.: Atria Wealth Solutions Inc. bought a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 9,709 shares of the biotechnology company’s stock, valued at approximately $686,000. Several other hedge funds and other institutional investors also […] - 2025-08-13 04:49:08
Natixis Advisors LLC Grows Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Natixis Advisors LLC raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 68.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,226 shares of the biotechnology company’s stock after buying an additional 13,488 shares during the quarter. Natixis Advisors […] - 2025-08-08 07:20:44
Guggenheim Issues Positive Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price: BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its target price hoisted by investment analysts at Guggenheim from $101.00 to $106.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 78.27% from the company’s current […] - 2025-08-08 04:26:58
BMRN Makes Bullish Cross Above Critical Moving Average: In trading on Tuesday, shares of BioMarin Pharmaceutical Inc (Symbol: BMRN) crossed above their 200 day moving average of $63.38, changing hands as high as $63.97 per share. BioMarin Pharmaceutical Inc shares are currently trading up about 5.7% on the day. The chart below show - 2025-08-05 12:47:37
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $93.74 Average Target Price from Analysts: Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) have been assigned an average rating of “Moderate Buy” from the twenty-four research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and eighteen have given a buy recommendation to the company. […] - 2025-08-05 02:55:15
Biomarin Pharmaceutical Q2 25 Earnings Conference Call At 4:30 PM ET: (RTTNews) - Biomarin Pharmaceutical Inc. (BMRN) will host a conference call at 4:30 PM ET on August 4, 2025, to discuss Q2 25 earnings results. - 2025-08-04 08:30:49
Signaturefd LLC Increases Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Signaturefd LLC boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 19.1% during the 1st quarter, Holdings Channel reports. The institutional investor owned 2,191 shares of the biotechnology company’s stock after acquiring an additional 352 shares during the period. Signaturefd LLC’s holdings in BioMarin Pharmaceutical were worth $155,000 as of […] - 2025-07-21 05:36:50
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Nisa Investment Advisors LLC: Nisa Investment Advisors LLC lifted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.0% in the first quarter, Holdings Channel reports. The firm owned 4,572 shares of the biotechnology company’s stock after buying an additional 217 shares during the period. Nisa Investment Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $323,000 as […] - 2025-07-17 06:25:00
Cerity Partners LLC Raises Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Cerity Partners LLC raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 203.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 84,832 shares of the biotechnology company’s stock after acquiring an additional 56,897 shares during the period. […] - 2025-07-17 05:51:03
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Raised to $113.00: BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective upped by JPMorgan Chase & Co. from $108.00 to $113.00 in a research report sent to investors on Monday morning,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biotechnology company’s stock. Other equities analysts have also issued research reports about the […] - 2025-07-17 04:48:52
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Xponance Inc.: Xponance Inc. raised its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 31,877 shares of the biotechnology company’s stock after buying an additional 202 shares during the quarter. Xponance Inc.’s holdings in BioMarin Pharmaceutical were worth […] - 2025-07-15 07:02:50
D.A. Davidson & CO. Has $480,000 Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): D.A. Davidson & CO. lessened its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 9.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,788 shares of the biotechnology company’s stock after selling 746 shares during the quarter. D.A. Davidson […] - 2025-07-11 05:32:53
Brokerages Set BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) PT at $93.61: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the firm, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The average 1 […] - 2025-07-11 02:56:50
Principal Financial Group Inc. Boosts Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Principal Financial Group Inc. lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.3% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 455,485 shares of the biotechnology company’s stock after purchasing an additional 1,549 shares during […] - 2025-07-08 06:26:49
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Sumitomo Mitsui Trust Group Inc.: Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.6% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 467,245 shares of the biotechnology company’s stock after selling 2,798 shares during the period. Sumitomo Mitsui Trust Group […] - 2025-07-03 06:13:02
Bessemer Group Inc. Has $327,000 Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Bessemer Group Inc. reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,618 shares of the biotechnology company’s stock after selling 683 shares during the quarter. Bessemer Group Inc.’s […] - 2025-07-03 05:00:50
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Robeco Institutional Asset Management B.V.: Robeco Institutional Asset Management B.V. boosted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 97,261 shares of the biotechnology company’s stock after purchasing an additional 10,687 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in BioMarin Pharmaceutical were […] - 2025-06-30 05:06:50
Kentucky Retirement Systems Insurance Trust Fund Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Kentucky Retirement Systems Insurance Trust Fund acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,490 shares of the biotechnology company’s stock, valued at approximately $388,000. A number of other institutional investors have also […] - 2025-06-26 05:04:54
Kentucky Retirement Systems Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Kentucky Retirement Systems bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, HoldingsChannel.com reports. The institutional investor bought 12,890 shares of the biotechnology company’s stock, valued at approximately $911,000. Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance […] - 2025-06-25 05:40:49
Exchange Traded Concepts LLC Acquires 979 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Exchange Traded Concepts LLC boosted its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 5.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,796 shares of the biotechnology company’s stock after acquiring an additional 979 shares during the quarter. Exchange Traded […] - 2025-06-19 04:58:54
Mn Services Vermogensbeheer B.V. Boosts Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Mn Services Vermogensbeheer B.V. increased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 12.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,500 shares of the biotechnology company’s stock after buying an additional 3,800 shares during the period. Mn Services Vermogensbeheer […] - 2025-06-18 05:44:54
NorthCrest Asset Manangement LLC Acquires Shares of 4,885 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): NorthCrest Asset Manangement LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 4,885 shares of the biotechnology company’s stock, valued at approximately $345,000. Other hedge funds and […] - 2025-06-16 05:36:54
UMB Bank n.a. Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): UMB Bank n.a. grew its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 120.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,247 shares of the biotechnology company’s stock after acquiring an additional 1,228 shares during the period. UMB Bank […] - 2025-06-12 05:32:57
Gateway Investment Advisers LLC Cuts Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Gateway Investment Advisers LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 22.2% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,512 shares of the biotechnology company’s stock after selling 1,003 shares during the period. Gateway Investment Advisers LLC’s […] - 2025-06-10 05:26:59
Tidal Investments LLC Sells 17,428 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Tidal Investments LLC lessened its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 57.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,039 shares of the biotechnology company’s stock after selling 17,428 shares during the quarter. Tidal Investments LLC’s holdings in BioMarin […] - 2025-05-27 05:21:04
Quantinno Capital Management LP Purchases Shares of 5,848 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Quantinno Capital Management LP bought a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 5,848 shares of the biotechnology company’s stock, valued at approximately $384,000. A number […] - 2025-05-26 04:58:58
BioMarin To Acquire Inozyme Pharma For About $270 Mln In Cash: (RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) and Inozyme Pharma, Inc. (INZY) Friday said that BioMarin has agreed to acquire Inozyme for about $270 million or $4 per share, in cash. - 2025-05-16 08:51:10
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $104.00 at The Goldman Sachs Group: BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price target cut by The Goldman Sachs Group from $124.00 to $104.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. Other research analysts have also issued reports about the company. Oppenheimer raised BioMarin Pharmaceutical […] - 2025-05-06 02:56:44
NewEdge Advisors LLC Purchases 3,121 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): NewEdge Advisors LLC increased its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 1,200.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,381 shares of the biotechnology company’s stock after buying an additional 3,121 shares during the […] - 2025-05-02 05:18:50

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.